TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition
Charles P. Theuer, M.D., Ph.D., President and Chief Executive
Officer of TRACON Pharmaceuticals, Inc. (TRACON), and other
executive officers will be presenting information that includes
an estimate of TRACONs December 31, 2016 cash, cash equivalents
and short-term investments and outstanding debt principal
balances, at various upcoming meetings beginning January 9,
2017.The information is attached as Exhibit 99.1 to this Current
Report on Form 8-K.
Item 7.01 Regulation FD Disclosure.
Charles P. Theuer, M.D., Ph.D., and other executive officers will
be presenting the information attached as Exhibit 99.1 to this
Current Report on Form 8-K at various upcoming meetings beginning
January 9, 2017.
By furnishing this information, TRACON makes no admission as to
the materiality of any information in this report. The
information contained in this report and the exhibit hereto is
intended to be considered in the context of TRACONs filings with
the Securities and Exchange Commission and other public
announcements that TRACON makes, by press release or otherwise,
from time to time. TRACON undertakes no duty or obligation to
publicly update or revise the information contained in this
report or the exhibit hereto, although it may do so from time to
time as its management believes is appropriate. Any such updating
may be made through the filing of other reports or documents with
the Securities and Exchange Commission, through press releases or
through other public disclosure.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
|
Exhibit Number |
Description of Exhibit |
|
99.1 |
Corporate Presentation, dated January 2017 |
About TRACON Pharmaceuticals, Inc. (NASDAQ:TCON)
TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (wet AMD) and fibrotic diseases. The Company’s research focuses on antibodies that bind to the endoglin receptor, which is essential to angiogenesis (the process of new blood vessel formation) and a contributor to fibrosis (tissue scarring). The Company’s lead product candidate, TRC105, is an endoglin antibody that is being developed for the treatment of multiple solid tumor types in combination with inhibitors of the vascular endothelial growth factor (VEGF) pathway. TRC205 is being developed for the treatment of fibrotic disease. The Company is also developing TRC102, a small molecule that is in clinical development for the treatment of lung cancer and glioblastoma. TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Recent Trading Information
TRACON Pharmaceuticals, Inc. (NASDAQ:TCON) closed its last trading session down -0.20 at 5.00 with 144,668 shares trading hands.
